ENTR-601-44
Duchenne Muscular Dystrophy (Exon 44 skipping)
Phase 1/2bActive
Key Facts
Indication
Duchenne Muscular Dystrophy (Exon 44 skipping)
Phase
Phase 1/2b
Status
Active
Company
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biotechnology company with a mission to overcome the fundamental challenge of intracellular drug delivery. Its core innovation is the Endosomal Escape Vehicle (EEV) platform, a versatile technology enabling the efficient delivery of therapeutic molecules into the cell cytoplasm. The company is advancing a pipeline of oligonucleotide-based candidates for serious genetic neuromuscular disorders, with its lead program, ENTR-601-44 for DMD exon 44 skipping, in Phase 1/2b trials. Entrada's strategy leverages its platform to target high-unmet-need diseases with validated biology but historically inaccessible targets.
View full company profile